This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Explore a selection of our essential drug information below, or:
Identification
- Summary
Oxolamine is a medication indicated in the treatment of a cough or upper respiratory tract inflammation.
- Generic Name
- Oxolamine
- DrugBank Accession Number
- DB13216
- Background
Oxolamine is not approved in the USA, it may be marketed elsewhere internationally as a cough suppressant 1. It is listed as a prescription drug in New Zealand legislation 2. Oxolamine is also approved in Taiwan for the treatment of respiratory tract inflamation 3.
- Type
- Small Molecule
- Groups
- Approved
- Structure
Structure for Oxolamine (DB13216)
- Weight
- Average: 245.326
Monoisotopic: 245.152812244 - Chemical Formula
- C14H19N3O
- Synonyms
- Oxolamina
- Oxolamine
- Oxolaminum
- External IDs
- 683 M
- AF 438
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Symptomatic treatment of Coughing •••••••••••• Used in combination for symptomatic treatment of Laryngitis Combination Product in combination with: Propyphenazone (DB13524) •••••••••••• ••••••••• ••••• ••••••••••• Used in combination for symptomatic treatment of Pharyngitis Combination Product in combination with: Propyphenazone (DB13524) •••••••••••• •••••• •••••••• ••••••••••• Used in combination for symptomatic treatment of Sinusitis Combination Product in combination with: Propyphenazone (DB13524) •••••••••••• ••••••••• ••••• ••••••••••• Used in combination for symptomatic treatment of Tonsillitis Combination Product in combination with: Propyphenazone (DB13524) •••••••••••• ••••••••• ••••• ••••••••••• - Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Product Ingredients
Ingredient UNII CAS InChI Key Oxolamine citrate K5X4XBR694 1949-20-8 RBZIGQJSMCOHSS-UHFFFAOYSA-N Oxolamine phosphate DMG78UE3PU 131378-45-5 PSCWWFOVTFSDGZ-UHFFFAOYSA-N - Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image ASE-COLD 120 mg+50mg+1mg/5 ml PEDİATRİK ŞURUP Oxolamine citrate (50 mg/5ml) + Acetaminophen (120 mg/5ml) + Chlorpheniramine maleate (1 mg/5ml) Syrup Oral LİLYUM İLAÇ VE KİMYA SAN. TİC. LTD. ŞTİ. 2019-05-07 Not applicable Turkey 
FORZA TABLET, 30 ADET Oxolamine citrate (100 mg) + Acetaminophen (250 mg) + Chlorpheniramine maleate (2 mg) + Phenylephrine hydrochloride (5 mg) Tablet Oral ALİ RAİF İLAÇ SAN. A.Ş. 1998-02-17 Not applicable Turkey KATARIN 120 MG+50 MG+1 MG/5 ML PEDIATRIK SURUP 100 ML Oxolamine citrate (50 mg) + Acetaminophen (120 mg) + Chlorpheniramine maleate (1 mg) Syrup Oral BİOFARMA İLAÇ SAN. VE TİC. A.Ş. 2003-04-29 Not applicable Turkey KATARİN 250 MG/100 MG/2 MG KAPSÜL, 15 ADET Oxolamine citrate (100 mg) + Acetaminophen (250 mg) + Chlorpheniramine (2 mg) Capsule Oral BİOFARMA İLAÇ SAN. VE TİC. A.Ş. 2020-08-14 Not applicable Turkey KATARİN 250 MG/100 MG/2 MG KAPSÜL, 30 ADET Oxolamine citrate (100 mg) + Acetaminophen (250 mg) + Chlorpheniramine (2 mg) Capsule Oral BİOFARMA İLAÇ SAN. VE TİC. A.Ş. 1968-12-09 Not applicable Turkey - Unapproved/Other Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image PERBRONS 10 MG 120 ML SURUP Oxolamine (10 mg) Syrup Oral CASEL ECZACI CAHİT SELİMOĞLU İLAÇ SAN. VE TİC. LTD. ŞTİ. 2018-12-31 Not applicable Turkey PEREBRON 50MG/5 ML 120 ML SURUP Oxolamine phosphate (50 mg/5ml) Syrup Oral ANGELİNİ İLAÇ SAN. VE TİC. A.Ş. 2013-01-29 Not applicable Turkey
Categories
- ATC Codes
- R05DB07 — Oxolamine
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as phenyloxadiazoles. These are polycyclic aromatic compounds containing a benzene ring linked to a 1,2,4-oxadiazole ring through a CC or CN bond.
- Kingdom
- Organic compounds
- Super Class
- Organoheterocyclic compounds
- Class
- Azoles
- Sub Class
- Oxadiazoles
- Direct Parent
- Phenyloxadiazoles
- Alternative Parents
- Aralkylamines / Benzene and substituted derivatives / Heteroaromatic compounds / Trialkylamines / Oxacyclic compounds / Azacyclic compounds / Organopnictogen compounds / Organooxygen compounds / Hydrocarbon derivatives
- Substituents
- Amine / Aralkylamine / Aromatic heteromonocyclic compound / Azacycle / Benzenoid / Heteroaromatic compound / Hydrocarbon derivative / Monocyclic benzene moiety / Organic nitrogen compound / Organic oxygen compound
- Molecular Framework
- Aromatic heteromonocyclic compounds
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 90BEA145GY
- CAS number
- 959-14-8
- InChI Key
- IDCHQQSVJAAUQQ-UHFFFAOYSA-N
- InChI
- InChI=1S/C14H19N3O/c1-3-17(4-2)11-10-13-15-14(16-18-13)12-8-6-5-7-9-12/h5-9H,3-4,10-11H2,1-2H3
- IUPAC Name
- diethyl[2-(3-phenyl-1,2,4-oxadiazol-5-yl)ethyl]amine
- SMILES
- CCN(CC)CCC1=NC(=NO1)C1=CC=CC=C1
References
- General References
- External Links
- ChemSpider
- 13143
- 32658
- ChEBI
- 94607
- ChEMBL
- CHEMBL1620875
- ZINC
- ZINC000000001874
- Wikipedia
- Oxolamine
Clinical Trials
- Clinical Trials
Clinical Trial & Rare Diseases Add-on Data Package
Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package Phase Status Purpose Conditions Count Start Date Why Stopped 100+ additional columns Unlock 175K+ rows when you subscribe.View sample data
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Syrup Oral 1200 mg Syrup Oral 62.4 mg/5ml Tablet Oral Solution Oral Capsule Oral Tablet, coated Oral Syrup Oral 50 mg/5ml Granule, effervescent Oral Syrup Oral Syrup Oral 10 mg Pill Suppository Syrup Oral Tablet 0.2 gr Syrup Oral 100 ml Syrup Oral 120 ml Syrup Oral 1.000 g Tablet Suppository Rectal - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.277 mg/mL ALOGPS logP 2.7 ALOGPS logP 3.14 Chemaxon logS -3 ALOGPS pKa (Strongest Basic) 8.96 Chemaxon Physiological Charge 1 Chemaxon Hydrogen Acceptor Count 3 Chemaxon Hydrogen Donor Count 0 Chemaxon Polar Surface Area 42.16 Å2 Chemaxon Rotatable Bond Count 6 Chemaxon Refractivity 84.15 m3·mol-1 Chemaxon Polarizability 28.59 Å3 Chemaxon Number of Rings 2 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS splash10-0kbr-9510000000-ae8477d8fa7555b8a25f Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS splash10-0002-1090000000-9fe5d65db66ca80d5b64 Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS splash10-0006-1090000000-89db599e44e327529840 Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS splash10-0002-1390000000-48ccae45dfc9e4260af6 Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS splash10-0udi-1910000000-b5e3bf76e617c52731db Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS splash10-0fb9-9500000000-a39ce233aadb2aadfd24 Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS splash10-0fb9-9810000000-c582240cce9652b46c15 Predicted 1H NMR Spectrum 1D NMR Not Applicable Predicted 13C NMR Spectrum 1D NMR Not Applicable - Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 166.470955 predictedDarkChem Lite v0.1.0 [M-H]- 158.07903 predictedDeepCCS 1.0 (2019) [M+H]+ 166.758455 predictedDarkChem Lite v0.1.0 [M+H]+ 160.43703 predictedDeepCCS 1.0 (2019) [M+Na]+ 166.732255 predictedDarkChem Lite v0.1.0 [M+Na]+ 166.53017 predictedDeepCCS 1.0 (2019)
Drug created at June 23, 2017 20:37 / Updated at June 05, 2021 09:13